Kezar Life Sciences Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Kezar Life Sciences, Inc. (KZR) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
Operating Activities
Net Income-83.74-101.87-68.24-54.63-41.74-35.09-23.17
Depreciation & Amortization1.041.07-0.173.371.540.320.69
Stock Based Compensation13.0118.1414.017.604.940.000.00
Change in Working Capital-1.304.71-4.371.22-2.012.210.06
Change in Accounts Payable-3.156.351.811.220.310.000.00
Change in Other Working Capital1.850.240.220.01-2.320.000.00
Other Operating Activities-3.230.2413.917.612.622.680.00
Net Cash from Operating Activities-74.21-81.65-58.85-42.44-36.95-29.88-20.79
Investing Activities
Capital Expenditures-0.03-1.811.580.32-0.190.61-1.11
Purchases of Investments-91.34-180.40-332.20-28.13-56.300.000.00
Sales/Maturities of Investments171.79258.25-89.81-28.13-56.3021.03-82.79
Net Cash from Investing Activities80.4376.05-91.39-28.44-56.5020.42-83.90
Financing Activities
Common Stock Issued0.100.64126.54103.0599.640.0077.70
Other Financing Activities0.000.00126.54100.9799.190.000.00
Net Cash from Financing Activities0.100.64127.86112.5999.640.2777.91
Summary
Effect of Forex Changes on Cash-0.060.00-0.05-0.050.08-0.05-0.08
Net Change in Cash6.26-4.96-22.3841.706.28-9.23-26.78
Cash at Beginning of Period35.4940.4662.8821.2314.9524.1851.05
Cash at End of Period41.7535.4940.4662.8821.2314.9524.18
Free Cash Flow-74.24-83.46-60.42-42.75-37.14-30.48-21.91
Supplemental Disclosures
Interest Paid1.341.320.970.070.000.000.00